Business
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing
About this update from Apogee Therapeutics, Inc.
[{"type":"text","content":"SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis was accepted for a late-breaker oral presentation at the upcoming EADV Congress 2025, to be held in Paris, France from September 17-20, 2025. The Company will also present multiple poster presentations highlighting APG777’s best-in-class potential including data supporting its combination strategy. “These presentations highlighting our lead program, APG777, and earlier stage programs, underscore our commitment to bringing new treatment options that provide strong efficacy and reduce injection burden for patients living with I&I conditions,” said Michael Henderson, M.D., Chief Executive Officer of Apogee. “In July, we announced 16-week topline data from the APEX clinical trial, in which APG777 met the primary and secondary endpoints, reinforcing its potentially best-in-class profile for moderate-to-severe atopic dermatitis as the only biologic being tested out to every 3- and 6-month dosing in maintenance. Additionally, previously reported healthy volunteer data of APG990 demonstrated an extended PK and positive tolerability profile, supporting our combination approach for this program with APG279, a coformulation of APG777 and APG990 that has the potential to inhibit Type 1, Type 2 and Type 3 inflammation, broadening the reach of patients we can potentially treat. We look forward to presenting these findings to the scientific community at EADV this year.” EADV Congress 2025 Presentation Details: Late-Breaker Oral Presentation: Title: APG777, a Novel, Half-Life Extended Anti-IL-13 Antibody, Demonstrates Safety and Efficacy in Moderate-to-Severe Atopic Dermatitis: 16-Week Results from the Phase 2 APEX Study (D3T01.4A)Presenter: Emma Guttman-Yassky, M.D., Ph.D., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York CityDate/Time: Friday, September 19, 4:00pm CEST / 10:00am ESTRoom: Paris Nord Poster Presentations: Title: A...